azathioprine has been researched along with Neoplasms in 196 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatments of myasthenia gravis (MG) usually include immunosuppressants such as glucocorticoids, tacrolimus, and azathioprine (AZA)." | 9.12 | Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis. ( Jiang, B; Jin, T; Shi, T; Wang, M; Xu, B; Xu, L; Zhang, Z, 2021) |
| "Azathioprine is the most widely used immunosuppressive treatment in multiple sclerosis (MS)." | 8.84 | Azathioprine for multiple sclerosis. ( Casetta, I; Filippini, G; Iuliano, G, 2007) |
| "To evaluate the association between the use of azathioprine and risk of cancer in patients with non-thymoma myasthenia gravis (MG) in a nationwide setting." | 7.79 | Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. ( Friis, S; Gaist, D; Hallas, J; Hansen, K; Jensen, PE; Pedersen, EG; Pottegård, A, 2013) |
| "The Rheumatoid Arthritis Azathioprine Registry (RAAR) was established in 1982 to examine the safety of azathioprine (AZA) and other disease modifying agents (DMARD) in the treatment of RA." | 7.68 | Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. ( Hickey, AR; Maguire, L; Matteson, EL; Tilson, HH; Urowitz, MB, 1991) |
| "Two hundred and two patients with rheumatoid arthritis (RA) starting treatment with large doses of azathioprine (median 300 mg/day) between 1964 and 1974 were followed up until March 1984." | 7.67 | Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. ( Evans, SJ; Hazleman, B; Petrie, J; Silman, AJ, 1988) |
| "Since 1967, 211 probable or definite multiple sclerosis (MS) patients have received azathioprine (100 mg daily) as primary immunosuppressive treatment." | 7.67 | [Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience]. ( de Saxcé, H; Lhermitte, F; Loridan, M; Marteau, R; Roullet, E, 1984) |
| "Therapy with azathioprine and cyclophosphamide is described as reducing disease activity in rheumatoid arthritis." | 7.66 | Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis. ( Decker, JL, 1983) |
| "Our experience with azathioprine in the treatment of rheumatoid arthritis covers ten years, during which 91 rheumatoid patients (66 female and 25 male) received this drug, with a median treatment period of 36 months." | 7.66 | Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience. ( Boerbooms, AM; Kruijsen, MW; Speerstra, F; van Beusekom, HJ; van de Putte, LB; Vandenbroucke, JP, 1982) |
| "A retrospective review of the literature has been carried out to determine laboratory abnormalities occurring in patients with rheumatoid arthritis (RA) treated with azathioprine, in order to establish a profile for this agent in the treatment of this disease." | 7.66 | Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. ( Pelkey, J; Whisnant, JK, 1982) |
| "The risk of malignancy associated with sequential disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) is uncertain." | 5.62 | Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study. ( Benedetti, MD; Caputo, D; d'Arma, A; Di Tella, S; La Mantia, L; Lillini, R; Marangi, A; Mendozzi, L; Rovaris, M; Sant, M; Turatti, M, 2021) |
| " The results are suggestive of a dose-response relationship with no significant risk during the first years of treatment and a possible increased risk after about 10 years of continuous therapy." | 5.29 | Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. ( Adeleine, P; Aimard, G; Confavreux, C; Grimaud, J; Moreau, T; Saddier, P, 1996) |
| "There were more deaths from neoplasia and ischaemic heart disease in the younger age group." | 5.26 | Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. ( Hanka, R; Hazleman, BL; Lewis, P; Roberts, S, 1980) |
| "More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine." | 5.19 | Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. ( Aumaître, O; Blanchard-Delaunay, C; Bonnotte, B; Carron, PL; Cohen, P; Daugas, E; Decaux, O; Ducret, M; Gobert, P; Godmer, P; Guillevin, L; Hamidou, M; Hatron, PY; Karras, A; Khouatra, C; Limal, N; Mahr, A; Maurier, F; Mouthon, L; Ninet, J; Pagnoux, C; Papo, T; Puéchal, X; Quémeneur, T; Ravaud, P, 2014) |
| "Treatments of myasthenia gravis (MG) usually include immunosuppressants such as glucocorticoids, tacrolimus, and azathioprine (AZA)." | 5.12 | Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis. ( Jiang, B; Jin, T; Shi, T; Wang, M; Xu, B; Xu, L; Zhang, Z, 2021) |
| " It discusses the company's epidemiologic approach to the question of association between treatment with disease-modifying antirheumatic drugs, one of which is manufactured by Burroughs Wellcome Company (Imuran brand azathioprine) and a possible increased risk of neoplasms in patients receiving these drugs as treatment for their rheumatoid arthritis." | 5.05 | Pharmaco-epidemiology--drugs, arthritis, and neoplasms: industry contribution to the data. ( Tilson, HH; Whisnant, J, 1985) |
| "Preliminary data suggest a possible association between the use of azathioprine, cyclophosphamide, and cyclosporine and increased susceptibility to cancer in patients with pemphigus and pemphigoid." | 4.86 | Association between cancer and immunosuppressive therapy--analysis of selected studies in pemphigus and pemphigoid. ( Ahmed, AR; Christen, WG; Gürcan, HM; Keskin, DB; Mabrouk, D, 2010) |
| "Azathioprine is the most widely used immunosuppressive treatment in multiple sclerosis (MS)." | 4.84 | Azathioprine for multiple sclerosis. ( Casetta, I; Filippini, G; Iuliano, G, 2007) |
| "To evaluate the association between the use of azathioprine and risk of cancer in patients with non-thymoma myasthenia gravis (MG) in a nationwide setting." | 3.79 | Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. ( Friis, S; Gaist, D; Hallas, J; Hansen, K; Jensen, PE; Pedersen, EG; Pottegård, A, 2013) |
| ") and treatments received (Azathioprine, mercaptopurine, infliximab, adalimumab or other immunomodulators), as well as neoplasms incidence." | 3.79 | Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain. ( Cabello-Tapia, MJ; De Teresa-Galván, J; Gómez-García, M; Redondo-Cerezo, E; Sánchez-Capilla, AD, 2013) |
| " In univariate analysis, older age at PM/DM onset, anemia, thrombocytopenia, leukopenia, diabetes mellitus, ILD, cancer, and non-use of azathioprine were associated with higher mortality (p = 0." | 3.77 | Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. ( Chang, HC; Chen, IJ; Ho, HH; Kuo, CF; Luo, SF; See, LC; Shen, YM; Wu, YJ; Yu, KH, 2011) |
| "Extrapolation from transplant, rheumatology, skin disease, and inflammatory bowel disease cohorts to the ocular inflammation setting suggest that: 1) alkylating agents increase hematologic malignancy risk and cyclophosphamide increases bladder cancer risk, but less so with < or =18 months' duration of therapy and hydration, respectively; 2) calcineurin inhibitors and azathioprine probably do not increase total cancer risk to a detectable degree, except perhaps some other risk factors (uncommon in ocular inflammation patients) might interact with the former to raise risk; 3) tumor necrosis factor (TNF) inhibitors may accelerate diagnosis of cancer in the first six to 12 months, but probably do not increase long-term cancer risk; and 4) changes in risk with methotrexate, mycophenolate mofetil, and daclizumab appear negligible, although nontransplant data are limited for the latter agents." | 3.74 | Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. ( Daniel, E; Foster, CS; Gangaputra, S; Helzlsouer, KJ; Jabs, DA; Kempen, JH; Levy-Clarke, GA; Nussenblatt, RB; Rosenbaum, JT; Suhler, EB; Thorne, JE, 2008) |
| "The aim of this study was to evaluate the long-term adverse effect (AE) profile of azathioprine (AZA) plus methylprednisolone combined immunosuppressive treatment in myasthenia gravis (MG) in a larger patient cohort." | 3.73 | Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients. ( Fornadi, L; Komoly, S; Lovas, G; Rozsa, C; Szabo, G, 2006) |
| "Treatment with prednisolone and azathioprine is beneficial in ameliorating the clinical course of a subset of IgAN patients with heavy proteinuria or impaired renal function." | 3.72 | Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. ( Ahuja, M; Brown, CB; Davlouros, P; El Nahas, AM; Goumenos, DS; Shortland, JR; Vlachojannis, JG, 2003) |
| "The Rheumatoid Arthritis Azathioprine Registry (RAAR) was established in 1982 to examine the safety of azathioprine (AZA) and other disease modifying agents (DMARD) in the treatment of RA." | 3.68 | Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. ( Hickey, AR; Maguire, L; Matteson, EL; Tilson, HH; Urowitz, MB, 1991) |
| "Since 1967, 211 probable or definite multiple sclerosis (MS) patients have received azathioprine (100 mg daily) as primary immunosuppressive treatment." | 3.67 | [Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience]. ( de Saxcé, H; Lhermitte, F; Loridan, M; Marteau, R; Roullet, E, 1984) |
| "To determine the frequency, predisposing factors and consequences of extrahepatic malignancy following long-term immunosuppressive therapy of severe HBsAg-negative chronic active hepatitis, 149 patients who had received prednisone (20 mg daily) or prednisone (10 mg daily) in combination with azathioprine (50 mg daily) for at least 6 months were evaluated systematically for 109 +/- 5 months (range: 7 to 223 months)." | 3.67 | Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. ( Beaver, SJ; Czaja, AJ; Go, VL; Wang, KK, 1989) |
| "Two hundred and two patients with rheumatoid arthritis (RA) starting treatment with large doses of azathioprine (median 300 mg/day) between 1964 and 1974 were followed up until March 1984." | 3.67 | Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. ( Evans, SJ; Hazleman, B; Petrie, J; Silman, AJ, 1988) |
| "A prospective study in the United Kingdom of 1,634 patients without transplants treated with immunosuppressive drugs (68 percent with azathioprine, 28 percent with cyclophosphamide) found an excess of non-Hodgkin's lymphoma and squamous cell skin cancer, suggesting that the excesses (although larger) of the same malignancies found among transplant recipients are not due solely to the foreign antigens of the graft." | 3.67 | Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. ( Kinlen, LJ, 1985) |
| "A retrospective review of the literature has been carried out to determine laboratory abnormalities occurring in patients with rheumatoid arthritis (RA) treated with azathioprine, in order to establish a profile for this agent in the treatment of this disease." | 3.66 | Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. ( Pelkey, J; Whisnant, JK, 1982) |
| "Our experience with azathioprine in the treatment of rheumatoid arthritis covers ten years, during which 91 rheumatoid patients (66 female and 25 male) received this drug, with a median treatment period of 36 months." | 3.66 | Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience. ( Boerbooms, AM; Kruijsen, MW; Speerstra, F; van Beusekom, HJ; van de Putte, LB; Vandenbroucke, JP, 1982) |
| "Therapy with azathioprine and cyclophosphamide is described as reducing disease activity in rheumatoid arthritis." | 3.66 | Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis. ( Decker, JL, 1983) |
| "Mycophenolic acid (MPA) is an immunosuppressive drug commonly used for prophylaxis of graft rejection in solid organ transplant recipients." | 2.82 | Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis. ( Hanprasertpong, N; Hirunsatitpron, P; Koonrungsesomboon, N; Noppakun, K; Pruksakorn, D; Teekachunhatean, S, 2022) |
| "The incidence of cancer was 22." | 2.73 | 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. ( Benoit, G; Cantarovich, M; Charpentier, B; Durrbach, A; Hiesse, C; Ladouceur, M, 2008) |
| "Rates of malignancy were within published ranges for transplant recipients." | 2.68 | Mycophenolate mofetil for maintenance therapy in kidney transplantation. ( Gonwa, TA, 1996) |
| "The incidence of cancer in patients receiving low-dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high-dose cyclosporin and prednisolone none of 23 and in those administered high-dose cyclosporin, nifedipine and prednisolone one of 29." | 2.67 | Triple therapy and incidence of de novo cancer in renal transplant recipients. ( Bell, PR; Butt, ZA; Donnelly, PK; Kehinde, EO; Morgan, JD; Petermann, A; Veitch, PS, 1994) |
| "The overall malignancy risk in patients with AAV has decreased, most likely as a result of recent changes in therapeutic regimen, that is, a decrease in the exposure to cyclophosphamide." | 2.58 | Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy. ( Bajema, IM; van Daalen, EE; Wester Trejo, MAC, 2018) |
| " Fortunately, the absolute incidence of serious toxicity remains low, and an improved understanding of how best to minimize risk and the recognition of groups of patients at higher risk of toxicity from thiopurines means that they remain a relatively safe therapy in the majority of patients." | 2.52 | Toxicity and response to thiopurines in patients with inflammatory bowel disease. ( Goldberg, R; Irving, PM, 2015) |
| "Subgroup SIR for cancers at all sites were 1." | 2.47 | Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. ( Flossmann, O; Harper, L; Heijl, C; Höglund, P; Mahr, A; Scott, DG; Stücker, I; Watts, RA; Westman, K, 2011) |
| "Azathioprine (AZA) is a purine analogue which has been used in the treatment of multiple sclerosis (MS) for over 30 years." | 2.46 | [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?]. ( Schmidt, S, 2010) |
| "The frequency of posttransplantation tumors is 2 to 4-fold compared to the non-transplanted population, and the distribution of tumor types is also different." | 2.44 | [Malignant tumors following renal transplantation]. ( Járay, J; Végso, G, 2007) |
| "Thiopurines have diverse clinical applications and their long-term use as anti-rejection drugs in transplant patients has been associated with a significantly increased risk of various types of cancer." | 2.44 | Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. ( Attard, N; Karran, P, 2008) |
| "In fact, it is expected that cancer will surpass cardiovascular complications as the leading cause of death in transplant patients within the next 2 decades." | 2.43 | Malignancy after transplantation. ( Buell, JF; Gross, TG; Woodle, ES, 2005) |
| "Reduced malignancy incidence recently reported with TOR inhibitors is compared with that of conventional immunosuppression." | 2.43 | Post-transplant de novo malignancies in renal transplant recipients: the past and present. ( Cheng, Y; Cherikh, WS; Hanto, DW; Kauffman, HM; McBride, MA, 2006) |
| "Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications." | 2.42 | Guidelines for prescribing azathioprine in dermatology. ( Anstey, AV; Reynolds, NJ; Wakelin, S, 2004) |
| " In terms of reproductive and developmental toxicity, cyclosporine produces some adverse effects in both experimental animals and humans." | 2.39 | International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosp ( Mattison, DR; Olshan, AF; Zwanenburg, TS, 1994) |
| "Azathioprine has a good safety profile and is preferred by most dermatologists for the treatment of bullous pemphigoid, cutaneous vasculitides, chronic eczematous dermatitides, and cutaneous manifestations of connective tissue diseases." | 2.38 | Immunosuppressive agents in dermatology. ( Ho, VC; Zloty, DM, 1993) |
| "Then we ascertained overall and cancer-specific mortalities by National Death Index linkage." | 1.91 | Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality. ( Acharya, NR; Artornsombudh, P; Begum, HA; Bhatt, NP; Buchanich, JM; Daniel, E; Dreger, KA; Dunn, JP; Fitzgerald, TD; Foster, CS; Gangaputra, SS; Goldstein, DA; Helzlsouer, KJ; Holland, GN; Jabs, DA; Kaçmaz, RO; Kempen, JH; Khachatryan, N; Kothari, S; Leiderman, YI; Levy-Clarke, GA; Liesegang, TL; Lowder, CY; Maghsoudlou, A; Newcomb, CW; Nussenblatt, RB; Pak, CM; Payal, AR; Pujari, SS; Read, RW; Rosenbaum, JT; Sen, HN; Sobrin, L; Suga, HK; Suhler, EB; Thorne, JE; Washington, TL, 2023) |
| "Since cancer diagnosis, 5." | 1.91 | Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials. ( Atkins, MB; Carlos, RC; Fenske, TS; Gareen, IF; Herman, BA; Hodi, FS; Kircher, SM; Kumar, S; Kyriakopoulos, CE; Land, SR; Lee, JW; Mayer, IA; Neal, JW; Ostroff, JS; Park, ER; Rosen, RL; Saba, NF; Shanafelt, TD; Streck, JM; Tempany, C; Wagner, LI; Walter, AW, 2023) |
| "The risk of malignancy associated with sequential disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) is uncertain." | 1.62 | Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study. ( Benedetti, MD; Caputo, D; d'Arma, A; Di Tella, S; La Mantia, L; Lillini, R; Marangi, A; Mendozzi, L; Rovaris, M; Sant, M; Turatti, M, 2021) |
| "Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies." | 1.62 | Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. ( Beukers, R; Bodelier, A; de Boer, N; de Lima, A; Depla, ACTM; Dijkstra, G; Erler, N; Escher, JC; Gilissen, L; Hoentjen, F; Jansen, JM; Kanis, SL; Kuyvenhoven, J; Mahmmod, N; Mallant-Hent, RC; Modderman, S; Noruzi, A; Oldenburg, B; Oostenbrug, LE; Pierik, M; Romberg-Camps, M; Ter Borg, PCJ; Thijs, W; van der Meulen-de Jong, AE; van der Woude, CJ; van Dijk, ARM; West, R, 2021) |
| "No significant risk for other intestinal cancers was found, especially for small bowel carcinoma." | 1.43 | Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. ( Charpentier, C; Cheddani, H; Dauchet, L; Dupas, JL; Fumery, M; Gower-Rousseau, C; Marie Bouvier, A; Pariente, B; Peyrin-Biroulet, L; Savoye, G, 2016) |
| "We aimed to analyse malignancy rates and predictors for the development of malignancies in a large German inflammatory bowel disease (IBD) cohort treated with thiopurines and/or anti-tumour necrosis factor (TNF) antibodies." | 1.40 | Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. ( Beigel, F; Brand, S; Breiteneicher, S; Göke, B; John, JM; Laubender, RP; Ochsenkühn, T; Schnitzler, F; Seiderer, J; Steinborn, A; Tillack, C; Van Steen, K, 2014) |
| "Azathioprine use was associated with an increased risk of overall cancer (rate ratio = 1." | 1.39 | Use of azathioprine and the risk of cancer in inflammatory bowel disease. ( Hviid, A; Jess, T; Pasternak, B; Schmiegelow, K; Svanström, H, 2013) |
| " The aim of this analysis was to compare both the long-term patient and graft survival and the incidences of adverse effects in recipients treated with standard triple-drug therapy (TDT) alone or with an additional HDI with ATG-F." | 1.39 | High graft protection and low incidences of infections, malignancies and other adverse effects with intra-operative high dose ATG-induction: a single centre cohort study of 760 cases. ( Kaden, J; Völp, A; Wesslau, C, 2013) |
| "Overall incidence of neoplasias was 30." | 1.36 | Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. ( Celik, S; Dengler, TJ; Doesch, AO; Ehlermann, P; Frankenstein, L; Katus, HA; Konstandin, M; Kristen, A; Müller, S; Sack, FU, 2010) |
| "Among the solid tumors, lymphoproliferative disorders (n=15), digestive tract (n=14), kidney and urinary tract (n=11), lung (n=10), and breast (n=3) carcinomas." | 1.36 | Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. ( Burgos, FJ; Fernández-Rodriguez, A; Galeano, C; Jiménez-Alvaro, S; Marcén, R; Quereda, C; Rivera, M; Teruel, JL, 2010) |
| "Case notes from Crohn's disease incidence studies in Cardiff were reviewed retrospectively for disease characteristics and follow-up information on drug therapy, and the need for surgery for Crohn's disease." | 1.36 | Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. ( Gunesh, S; Hawthorne, AB; Ramadas, AV; Thomas, GA; Williams, GT, 2010) |
| "Azathioprine is an accepted treatment of inflammatory bowel disease (IBD), but concerns exist regarding its carcinogenic potential." | 1.36 | Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. ( Armstrong, RG; Card, TR; West, J, 2010) |
| "We calculated the hazard ratio (HR) for cancer after exposure to an immunosuppressive drug, in models that controlled for other medications (anti-malarial drugs, systemic glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin), smoking, age, sex, race/ethnicity, geographic location, calendar year, SLE duration, and lupus damage scores." | 1.35 | The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. ( Alarcón, GS; Aranow, C; Bae, SC; Barr, S; Bernatsky, S; Boivin, JF; Clarke, AE; Dooley, MA; Edworthy, S; Fortin, PR; Ginzler, E; Gladman, D; Gordon, C; Isenberg, D; Joseph, L; Manzi, S; Petri, M; Rahman, A; Rajan, R; Ramsey-Goldman, R; Sénécal, JL; Urowitz, M; Zummer, M, 2008) |
| "The relative increased risk of breast cancer in MS women under IS treatment warrants further attention." | 1.35 | Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. ( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008) |
| "This potential for an anti-cancer effect is further supported by the emerging data on the use of PSIs/mTOR inhibitors in non-transplant oncology patients." | 1.34 | Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. ( Valantine, H, 2007) |
| "The incidence of malignancy, survival rate, and risk factors for malignancy were examined." | 1.34 | Risk factors for malignancy in Japanese renal transplant recipients. ( Ichimaru, N; Imamura, R; Imao, T; Isaka, Y; Kokado, Y; Namba, Y; Nonomura, N; Okumi, M; Okuyama, A; Takahara, S, 2007) |
| "Only four patients with extrathymic tumors had an associated thymoma." | 1.33 | Extrathymic malignancies in patients with myasthenia gravis. ( Abramsky, O; Argov, Z; Ben Hur, T; Karussis, D; Levin, N; Lossos, A; Siegal, T, 2005) |
| "The frequency of cancer-associated mortality was 11% that was 2% of the total lupus population." | 1.33 | [The occurrence of malignancies in a Hungarian lupus population]. ( Kiss, E; Szegedi, G; Szekanecz, E; Tarr, T; Zeher, M, 2006) |
| "The 5% incidence de novo tumors developing among patients treated with azathioprine and prednisolone (n = 241) was similar to the 5." | 1.32 | De novo tumors after kidney transplantation: the Budapest experience. ( Hídvégi, M; Járay, J; Langer, RM; Perner, F; Tóth, A; Végsö, G, 2003) |
| "Azathioprine was given to 626 of 2204 patients (855 with Crohn's disease and 1349 with ulcerative colitis)." | 1.31 | Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. ( Fraser, AG; Jewell, DP; Orchard, TR; Robinson, EM, 2002) |
| "The most frequently seen posttransplant neoplasms were squamous carcinoma of skin, basal cell carcinoma (BCC), posttransplant lymphoproliferative disease (PTLD) and gastro-intestinal (GI) cancer." | 1.31 | One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. ( Douglas, JF; McGeown, MG; Middleton, D, 2000) |
| " Before thiopurine dosage adjustments, TPMT-deficient patients experienced more frequent hospitalization, more platelet transfusions, and more missed doses of chemotherapy." | 1.31 | Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. ( Bomgaars, L; Coutre, S; Evans, WE; Holdsworth, M; Hon, YY; Janco, R; Kalwinsky, D; Keller, F; Khatib, Z; Kornegay, N; Krynetski, EY; Margolin, J; Murray, J; Quinn, J; Ravindranath, Y; Relling, MV; Ritchey, K; Roberts, W; Rogers, ZR; Schiff, D; Steuber, C; Tucci, F, 2001) |
| "Transplanted patients with cancer were found to have reduced DNA repair." | 1.31 | Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. ( Chagnac, A; Gafter, U; Herman, M; Korzets, A; Malachi, T; Ori, Y; Weinstein, T; Zevin, D, 2001) |
| "The incidences and sites of malignant neoplasms were analyzed in 285 kidney recipients, who had been followed up for 3007 patient-years." | 1.30 | Malignant neoplasm in kidney transplantation. ( Ebisui, C; Fukunishi, T; Hanafusa, T; Ichikawa, Y; Kishikawa, H; Nagano, S; Okuyama, A; Yazawa, K, 1998) |
| "9 cases of malignancy (4." | 1.30 | The incidence of malignancy in heart transplant recipients. ( Biernat, M; Drop, D; Dziatkowiak, A; Garlicki, M; Olszewska, B; Przybyłowski, P; Rudziński, P; Wierzbicki, K, 1998) |
| "In addition to any increased risk of malignancy that may be conferred by individual rheumatic diseases, there is a further risk of specific types of malignancy that is related to the duration of exposure to immunosuppressive drugs." | 1.30 | Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. ( Asten, P; Barrett, J; Symmons, D, 1999) |
| " The results are suggestive of a dose-response relationship with no significant risk during the first years of treatment and a possible increased risk after about 10 years of continuous therapy." | 1.29 | Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. ( Adeleine, P; Aimard, G; Confavreux, C; Grimaud, J; Moreau, T; Saddier, P, 1996) |
| "Among patients with extensive chronic ulcerative colitis there was no difference in cancer frequency between 86 who had received azathioprine and 180 matched patients who had never received it." | 1.29 | Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. ( Balkwill, AM; Connell, WR; Dickson, M; Kamm, MA; Lennard-Jones, JE; Ritchie, JK, 1994) |
| "Most of the excess deaths were due to malignancy." | 1.29 | Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. ( Finn, J; Jones, M; Symmons, D; Wolfe, F, 1996) |
| "A history of preexisting malignancy has been considered a contraindication to cardiac transplantation." | 1.28 | Cardiac transplantation in patients with preexisting malignancies. ( Clark, WR; Dillon, TA; Ladowski, JS; Peterson, AC; Schätzlein, MH; Scheeringa, RH; Sullivan, M, 1991) |
| "The incidence of malignant neoplasms in patients subjected to pharmacological immunosuppression following kidney transplantation is higher than that observed in the control population at large." | 1.27 | [Malignant neoplastic pathology in patients given a kidney transplant]. ( Boschiero, L; Dean, P; Faccincani, L; Muolo, A; Prati, GF; Recchia, G, 1987) |
| "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications." | 1.27 | Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. ( Hazleman, B, 1985) |
| " The correlation between these is poor, in many patients, at the dosage used in man." | 1.26 | The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. ( Hazleman, BL, 1982) |
| "There were more deaths from neoplasia and ischaemic heart disease in the younger age group." | 1.26 | Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. ( Hanka, R; Hazleman, BL; Lewis, P; Roberts, S, 1980) |
| "Patterns of infection are recognized, and this should enable the physician to plan a meaningful course of action when infection occurs in the compromised host." | 1.25 | Infections in the immunosuppressed patient. ( O'Loughlin, JM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 81 (41.33) | 18.7374 |
| 1990's | 36 (18.37) | 18.2507 |
| 2000's | 41 (20.92) | 29.6817 |
| 2010's | 28 (14.29) | 24.3611 |
| 2020's | 10 (5.10) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Helguera, AM | 1 |
| Cordeiro, MN | 1 |
| Pérez, MA | 1 |
| Combes, RD | 1 |
| González, MP | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Lok, SD | 1 |
| Wong, AW | 1 |
| Khor, YH | 1 |
| Ryerson, CJ | 1 |
| Johannson, KA | 1 |
| Martins, AL | 1 |
| Galhardi Gasparini, R | 1 |
| Sassaki, LY | 1 |
| Saad-Hossne, R | 1 |
| Ritter, AMV | 1 |
| Barreto, TB | 1 |
| Marcolino, T | 1 |
| Yang Santos, C | 1 |
| Streck, JM | 1 |
| Lee, JW | 1 |
| Walter, AW | 1 |
| Rosen, RL | 1 |
| Gareen, IF | 1 |
| Kircher, SM | 1 |
| Herman, BA | 1 |
| Carlos, RC | 1 |
| Kumar, S | 1 |
| Mayer, IA | 1 |
| Saba, NF | 1 |
| Fenske, TS | 1 |
| Neal, JW | 1 |
| Atkins, MB | 1 |
| Hodi, FS | 1 |
| Kyriakopoulos, CE | 1 |
| Tempany, C | 1 |
| Shanafelt, TD | 1 |
| Wagner, LI | 1 |
| Land, SR | 1 |
| Park, ER | 1 |
| Ostroff, JS | 1 |
| Kempen, JH | 2 |
| Newcomb, CW | 1 |
| Washington, TL | 1 |
| Foster, CS | 2 |
| Sobrin, L | 1 |
| Thorne, JE | 2 |
| Jabs, DA | 2 |
| Suhler, EB | 2 |
| Rosenbaum, JT | 2 |
| Sen, HN | 1 |
| Levy-Clarke, GA | 2 |
| Nussenblatt, RB | 2 |
| Bhatt, NP | 1 |
| Lowder, CY | 1 |
| Goldstein, DA | 1 |
| Leiderman, YI | 1 |
| Acharya, NR | 1 |
| Holland, GN | 1 |
| Read, RW | 1 |
| Dunn, JP | 1 |
| Dreger, KA | 1 |
| Artornsombudh, P | 1 |
| Begum, HA | 1 |
| Fitzgerald, TD | 1 |
| Kothari, S | 1 |
| Payal, AR | 1 |
| Daniel, E | 2 |
| Gangaputra, SS | 1 |
| Kaçmaz, RO | 1 |
| Liesegang, TL | 1 |
| Pujari, SS | 1 |
| Khachatryan, N | 1 |
| Maghsoudlou, A | 1 |
| Suga, HK | 1 |
| Pak, CM | 1 |
| Helzlsouer, KJ | 2 |
| Buchanich, JM | 1 |
| Jiang, N | 1 |
| Jin, S | 1 |
| Yu, C | 1 |
| Zhao, J | 1 |
| Wang, Q | 1 |
| Tian, X | 1 |
| Li, M | 1 |
| Zeng, X | 1 |
| Lorenzo-Vizcaya, A | 1 |
| Isenberg, D | 2 |
| La Mantia, L | 1 |
| Benedetti, MD | 1 |
| Sant, M | 1 |
| d'Arma, A | 1 |
| Di Tella, S | 1 |
| Lillini, R | 1 |
| Mendozzi, L | 1 |
| Marangi, A | 1 |
| Turatti, M | 1 |
| Caputo, D | 1 |
| Rovaris, M | 1 |
| Zhang, Z | 1 |
| Wang, M | 1 |
| Xu, L | 1 |
| Jiang, B | 1 |
| Jin, T | 1 |
| Shi, T | 1 |
| Xu, B | 1 |
| Hirunsatitpron, P | 1 |
| Hanprasertpong, N | 1 |
| Noppakun, K | 1 |
| Pruksakorn, D | 1 |
| Teekachunhatean, S | 1 |
| Koonrungsesomboon, N | 1 |
| Wester Trejo, MAC | 1 |
| Bajema, IM | 1 |
| van Daalen, EE | 1 |
| de Boer, NKH | 1 |
| Peyrin-Biroulet, L | 2 |
| Jharap, B | 1 |
| Sanderson, JD | 1 |
| Meijer, B | 1 |
| Atreya, I | 1 |
| Barclay, ML | 1 |
| Colombel, JF | 1 |
| Lopez, A | 1 |
| Beaugerie, L | 1 |
| Marinaki, AM | 1 |
| van Bodegraven, AA | 1 |
| Neurath, MF | 1 |
| Qiu, XY | 1 |
| Lu, MJ | 1 |
| Zhang, HJ | 1 |
| Pedersen, EG | 1 |
| Pottegård, A | 1 |
| Hallas, J | 1 |
| Friis, S | 1 |
| Hansen, K | 1 |
| Jensen, PE | 1 |
| Gaist, D | 1 |
| Pasternak, B | 1 |
| Svanström, H | 1 |
| Schmiegelow, K | 1 |
| Jess, T | 2 |
| Hviid, A | 1 |
| Kaden, J | 1 |
| Völp, A | 1 |
| Wesslau, C | 1 |
| Gómez-García, M | 1 |
| Cabello-Tapia, MJ | 1 |
| Sánchez-Capilla, AD | 1 |
| De Teresa-Galván, J | 1 |
| Redondo-Cerezo, E | 1 |
| Kittleson, MM | 1 |
| Kobashigawa, JA | 1 |
| Beigel, F | 1 |
| Steinborn, A | 1 |
| Schnitzler, F | 1 |
| Tillack, C | 1 |
| Breiteneicher, S | 1 |
| John, JM | 1 |
| Van Steen, K | 1 |
| Laubender, RP | 1 |
| Göke, B | 1 |
| Seiderer, J | 1 |
| Brand, S | 1 |
| Ochsenkühn, T | 1 |
| Guillevin, L | 1 |
| Pagnoux, C | 1 |
| Karras, A | 1 |
| Khouatra, C | 1 |
| Aumaître, O | 1 |
| Cohen, P | 1 |
| Maurier, F | 1 |
| Decaux, O | 1 |
| Ninet, J | 1 |
| Gobert, P | 1 |
| Quémeneur, T | 1 |
| Blanchard-Delaunay, C | 1 |
| Godmer, P | 1 |
| Puéchal, X | 1 |
| Carron, PL | 1 |
| Hatron, PY | 1 |
| Limal, N | 1 |
| Hamidou, M | 1 |
| Ducret, M | 1 |
| Daugas, E | 1 |
| Papo, T | 1 |
| Bonnotte, B | 1 |
| Mahr, A | 2 |
| Ravaud, P | 1 |
| Mouthon, L | 1 |
| Chaparro, M | 1 |
| Gisbert, JP | 1 |
| Rivinius, R | 1 |
| Helmschrott, M | 1 |
| Ruhparwar, A | 1 |
| Schmack, B | 1 |
| Klein, B | 1 |
| Erbel, C | 1 |
| Gleissner, CA | 1 |
| Akhavanpoor, M | 1 |
| Frankenstein, L | 2 |
| Darche, FF | 1 |
| Thomas, D | 1 |
| Ehlermann, P | 2 |
| Bruckner, T | 1 |
| Katus, HA | 2 |
| Doesch, AO | 2 |
| Goldberg, R | 1 |
| Irving, PM | 1 |
| Thervet, É | 1 |
| Cheddani, H | 1 |
| Dauchet, L | 1 |
| Fumery, M | 1 |
| Charpentier, C | 1 |
| Marie Bouvier, A | 1 |
| Dupas, JL | 1 |
| Pariente, B | 1 |
| Savoye, G | 1 |
| Gower-Rousseau, C | 1 |
| Gangaputra, S | 1 |
| Domhan, S | 1 |
| Zeier, M | 1 |
| Abdollahi, A | 1 |
| Cantarovich, M | 1 |
| Durrbach, A | 1 |
| Hiesse, C | 1 |
| Ladouceur, M | 1 |
| Benoit, G | 1 |
| Charpentier, B | 1 |
| Gallagher, M | 1 |
| Jardine, M | 1 |
| Perkovic, V | 1 |
| Cass, A | 1 |
| McDonald, S | 1 |
| Petrie, J | 2 |
| Eris, J | 1 |
| Armstrong, RG | 1 |
| West, J | 1 |
| Card, TR | 1 |
| Schmidt, S | 1 |
| Ramadas, AV | 1 |
| Gunesh, S | 1 |
| Thomas, GA | 1 |
| Williams, GT | 1 |
| Hawthorne, AB | 1 |
| Ruffolo, C | 1 |
| Scarpa, M | 1 |
| Bassi, N | 1 |
| Mabrouk, D | 1 |
| Gürcan, HM | 1 |
| Keskin, DB | 1 |
| Christen, WG | 1 |
| Ahmed, AR | 1 |
| Marcén, R | 1 |
| Galeano, C | 1 |
| Fernández-Rodriguez, A | 1 |
| Jiménez-Alvaro, S | 1 |
| Teruel, JL | 1 |
| Rivera, M | 1 |
| Burgos, FJ | 1 |
| Quereda, C | 1 |
| Müller, S | 1 |
| Konstandin, M | 1 |
| Celik, S | 1 |
| Kristen, A | 1 |
| Sack, FU | 1 |
| Dengler, TJ | 1 |
| Heijl, C | 1 |
| Harper, L | 1 |
| Flossmann, O | 1 |
| Stücker, I | 1 |
| Scott, DG | 1 |
| Watts, RA | 1 |
| Höglund, P | 1 |
| Westman, K | 1 |
| Yu, KH | 1 |
| Wu, YJ | 1 |
| Kuo, CF | 1 |
| See, LC | 1 |
| Shen, YM | 1 |
| Chang, HC | 1 |
| Luo, SF | 1 |
| Ho, HH | 1 |
| Chen, IJ | 1 |
| Meggitt, SJ | 1 |
| Anstey, AV | 2 |
| Mohd Mustapa, MF | 1 |
| Reynolds, NJ | 2 |
| Wakelin, S | 2 |
| Dasari, BV | 1 |
| McBrearty, A | 1 |
| Gardiner, K | 1 |
| Fraser, AG | 1 |
| Orchard, TR | 1 |
| Robinson, EM | 1 |
| Jewell, DP | 1 |
| Goumenos, DS | 1 |
| Davlouros, P | 1 |
| El Nahas, AM | 1 |
| Ahuja, M | 1 |
| Shortland, JR | 1 |
| Vlachojannis, JG | 1 |
| Brown, CB | 1 |
| Langer, RM | 1 |
| Járay, J | 2 |
| Tóth, A | 1 |
| Hídvégi, M | 1 |
| Végsö, G | 2 |
| Perner, F | 1 |
| Bakker, RC | 1 |
| Hollander, AA | 1 |
| Mallat, MJ | 1 |
| Bruijn, JA | 1 |
| Paul, LC | 1 |
| de Fijter, JW | 1 |
| MARCHIORO, TL | 1 |
| ROWLANDS, DT | 1 |
| RIFKIND, D | 1 |
| WADDELL, WR | 1 |
| STARZL, TE | 2 |
| FUDENBERG, H | 1 |
| MATHE, G | 1 |
| AMIEL, JL | 1 |
| SCHWARZENBERG, L | 1 |
| CATTAN, A | 1 |
| SCHNEIDER, M | 1 |
| DEVRIES, MJ | 1 |
| TUBIANA, M | 1 |
| LALANNE, C | 1 |
| BINET, JL | 1 |
| PAPIERNIK, M | 1 |
| SEMAN, G | 1 |
| MATSUKURA, M | 1 |
| MERY, AM | 1 |
| SCHWARZMANN, V | 1 |
| FLAISLER, A | 1 |
| MARTIN, DC | 1 |
| RUBINI, M | 1 |
| ROSEN, VJ | 1 |
| Miller, OF | 1 |
| Smith, LJ | 1 |
| Ferrara, EX | 1 |
| McAleer, IM | 1 |
| Kaplan, GW | 1 |
| Taylor, L | 1 |
| Hughes, RA | 1 |
| McPherson, K | 1 |
| Nero, P | 1 |
| Rahman, A | 2 |
| Isenberg, DA | 1 |
| Winther, KV | 1 |
| Langholz, E | 1 |
| Munkholm, P | 1 |
| Binder, V | 1 |
| David, KM | 1 |
| Morris, JA | 1 |
| Steffen, BJ | 1 |
| Chi-Burris, KS | 1 |
| Gotz, VP | 1 |
| Gordon, RD | 1 |
| Levin, N | 1 |
| Abramsky, O | 1 |
| Lossos, A | 1 |
| Karussis, D | 1 |
| Siegal, T | 1 |
| Argov, Z | 1 |
| Ben Hur, T | 1 |
| Buell, JF | 1 |
| Gross, TG | 1 |
| Woodle, ES | 1 |
| Stukov, AN | 1 |
| Gershanovich, ML | 1 |
| Filov, VA | 1 |
| Imianitov, EN | 1 |
| Kauffman, HM | 1 |
| Cherikh, WS | 1 |
| McBride, MA | 1 |
| Cheng, Y | 1 |
| Hanto, DW | 1 |
| Thaunat, O | 1 |
| Morelon, E | 1 |
| Rozsa, C | 1 |
| Lovas, G | 1 |
| Fornadi, L | 1 |
| Szabo, G | 1 |
| Komoly, S | 1 |
| Rawoot, A | 1 |
| Little, F | 1 |
| Heckmann, JM | 1 |
| Joss, N | 1 |
| Rodger, RS | 1 |
| McMillan, MA | 1 |
| Junor, BJ | 1 |
| Tarr, T | 1 |
| Szekanecz, E | 1 |
| Zeher, M | 1 |
| Szegedi, G | 1 |
| Kiss, E | 1 |
| Imao, T | 1 |
| Ichimaru, N | 1 |
| Takahara, S | 1 |
| Kokado, Y | 1 |
| Okumi, M | 1 |
| Imamura, R | 1 |
| Namba, Y | 1 |
| Isaka, Y | 1 |
| Nonomura, N | 1 |
| Okuyama, A | 2 |
| Valantine, H | 1 |
| Bernatsky, S | 1 |
| Joseph, L | 1 |
| Boivin, JF | 1 |
| Gordon, C | 1 |
| Urowitz, M | 1 |
| Gladman, D | 1 |
| Fortin, PR | 1 |
| Ginzler, E | 1 |
| Bae, SC | 1 |
| Barr, S | 1 |
| Edworthy, S | 1 |
| Petri, M | 1 |
| Alarcón, GS | 1 |
| Aranow, C | 1 |
| Dooley, MA | 1 |
| Rajan, R | 1 |
| Sénécal, JL | 1 |
| Zummer, M | 1 |
| Manzi, S | 1 |
| Ramsey-Goldman, R | 1 |
| Clarke, AE | 1 |
| Casetta, I | 1 |
| Iuliano, G | 1 |
| Filippini, G | 1 |
| Karran, P | 1 |
| Attard, N | 1 |
| Cheung, CY | 1 |
| Liu, YL | 1 |
| Wong, KM | 1 |
| Chan, HW | 1 |
| Chan, YH | 1 |
| Wong, HS | 1 |
| Chak, WL | 1 |
| Choi, KS | 1 |
| Chau, KF | 1 |
| Shek, CC | 1 |
| Li, CS | 1 |
| Lebrun, C | 1 |
| Debouverie, M | 1 |
| Vermersch, P | 1 |
| Clavelou, P | 1 |
| Rumbach, L | 1 |
| de Seze, J | 1 |
| Wiertlevski, S | 1 |
| Defer, G | 1 |
| Gout, O | 1 |
| Berthier, F | 1 |
| Danzon, A | 1 |
| Goldsmith, P | 1 |
| Lennox, G | 1 |
| Bhalla, N | 1 |
| McDonald, WI | 1 |
| Mertin, J | 1 |
| Lhermitte, F | 1 |
| Marteau, R | 1 |
| Roullet, E | 1 |
| de Saxcé, H | 1 |
| Loridan, M | 1 |
| Krel', AA | 1 |
| Kanevskaia, MZ | 1 |
| Rashchupkina, ZP | 1 |
| Bolotin, EV | 1 |
| Chichasova, NV | 1 |
| Huskisson, EC | 1 |
| Berliner, S | 1 |
| Shoenfeld, Y | 1 |
| Sidi, Y | 1 |
| Santo, M | 1 |
| Weinberger, A | 1 |
| Luria, D | 1 |
| Hazaz, B | 1 |
| Pecht, M | 1 |
| Zaizov, R | 1 |
| Pinkhas, J | 1 |
| Pascual Gómez, E | 1 |
| Decker, JL | 1 |
| Shamberger, RC | 1 |
| Devereux, DF | 1 |
| Brennan, MF | 1 |
| Penn, I | 4 |
| Speerstra, F | 1 |
| Boerbooms, AM | 1 |
| van de Putte, LB | 1 |
| van Beusekom, HJ | 1 |
| Kruijsen, MW | 1 |
| Vandenbroucke, JP | 1 |
| Balthazar, PA | 1 |
| Hazleman, BL | 2 |
| Paulus, HE | 1 |
| Whisnant, JK | 1 |
| Pelkey, J | 1 |
| Mills, PR | 1 |
| Boyle, P | 1 |
| Quigley, EM | 1 |
| Birnie, GG | 1 |
| Jarrett, F | 1 |
| Watkinson, G | 1 |
| MacSween, RN | 1 |
| Schmähl, D | 1 |
| Habs, M | 1 |
| Lorenz, M | 1 |
| Wagner, I | 1 |
| Lewis, P | 1 |
| Hanka, R | 1 |
| Roberts, S | 1 |
| Olshan, AF | 1 |
| Mattison, DR | 1 |
| Zwanenburg, TS | 1 |
| Dorent, R | 1 |
| Pavie, A | 1 |
| Nataf, P | 1 |
| Tedy, G | 1 |
| Vaissier, E | 1 |
| Ghoussoub, JJ | 1 |
| Bors, V | 1 |
| Gandjbakhch, I | 1 |
| Connell, WR | 1 |
| Kamm, MA | 1 |
| Dickson, M | 1 |
| Balkwill, AM | 1 |
| Ritchie, JK | 1 |
| Lennard-Jones, JE | 1 |
| Kehinde, EO | 1 |
| Petermann, A | 1 |
| Morgan, JD | 1 |
| Butt, ZA | 1 |
| Donnelly, PK | 1 |
| Veitch, PS | 1 |
| Bell, PR | 1 |
| Ritters, B | 1 |
| Grabensee, B | 1 |
| Heering, P | 1 |
| Shanahan, F | 1 |
| Bernstein, CN | 1 |
| Batiuk, TD | 1 |
| Barry, JM | 2 |
| Bennett, WM | 1 |
| Meyer, MM | 1 |
| Tolzman, D | 1 |
| Norman, DJ | 2 |
| Kahana, L | 1 |
| Stuart, FP | 1 |
| Thistlethwaite, JR | 1 |
| Shield, CF | 1 |
| Monaco, A | 1 |
| Dehlinger, J | 1 |
| Wu, SC | 1 |
| Van Horn, A | 1 |
| Haverty, TP | 1 |
| Ho, VC | 1 |
| Zloty, DM | 1 |
| Sheil, AG | 4 |
| Disney, AP | 3 |
| Mathew, TH | 3 |
| Amiss, N | 2 |
| Amato, MP | 1 |
| Pracucci, G | 1 |
| Ponziani, G | 1 |
| Siracusa, G | 1 |
| Fratiglioni, L | 1 |
| Amaducci, L | 1 |
| Confavreux, C | 1 |
| Saddier, P | 1 |
| Grimaud, J | 1 |
| Moreau, T | 1 |
| Adeleine, P | 1 |
| Aimard, G | 1 |
| Gonwa, TA | 1 |
| Ponticelli, C | 1 |
| Civati, G | 1 |
| Tarantino, A | 1 |
| Quarto di Palo, F | 2 |
| Corbetta, G | 1 |
| Minetti, L | 1 |
| Vegeto, A | 1 |
| Belli, L | 1 |
| Jones, M | 1 |
| Symmons, D | 2 |
| Finn, J | 1 |
| Wolfe, F | 1 |
| Büyükpamukçu, N | 1 |
| Karakayali, H | 1 |
| Bilgin, N | 1 |
| Bakr, MA | 1 |
| Sobh, M | 1 |
| el-Agroudy, A | 1 |
| Sally, S | 1 |
| Fouda, MA | 1 |
| el-Mekresh, M | 1 |
| Moustafa, F | 1 |
| el-Baz, M | 1 |
| Wafa, E | 1 |
| Ghoneim, MA | 1 |
| Dantal, J | 1 |
| Hourmant, M | 1 |
| Cantarovich, D | 1 |
| Giral, M | 1 |
| Blancho, G | 1 |
| Dreno, B | 1 |
| Soulillou, JP | 1 |
| Adamson, R | 1 |
| Obispo, E | 1 |
| Dychter, S | 1 |
| Dembitsky, W | 1 |
| Moreno-Cabral, R | 1 |
| Jaski, B | 1 |
| Gordon, J | 1 |
| Hoagland, P | 1 |
| Moore, K | 1 |
| King, J | 1 |
| Andrews, J | 1 |
| Rich, M | 1 |
| Daily, PO | 1 |
| Peddi, VR | 1 |
| Whiting, J | 1 |
| Weiskittel, PD | 1 |
| Alexander, JW | 1 |
| First, MR | 1 |
| Jonas, S | 1 |
| Guckelberger, O | 1 |
| Bechstein, WO | 1 |
| Berg, T | 1 |
| Müller, AR | 1 |
| Platz, KP | 1 |
| Tullius, SG | 1 |
| Settmacher, U | 1 |
| Steinmüller, T | 1 |
| Hopf, U | 1 |
| Neuhaus, P | 1 |
| Chuang, FR | 1 |
| Hsieh, H | 1 |
| Hsu, KT | 1 |
| Chien, YS | 1 |
| Chung, HM | 1 |
| Kishikawa, H | 1 |
| Ichikawa, Y | 1 |
| Yazawa, K | 1 |
| Hanafusa, T | 1 |
| Fukunishi, T | 1 |
| Ebisui, C | 1 |
| Nagano, S | 1 |
| Garlicki, M | 1 |
| Wierzbicki, K | 1 |
| Przybyłowski, P | 1 |
| Drop, D | 1 |
| Biernat, M | 1 |
| Rudziński, P | 1 |
| Olszewska, B | 1 |
| Dziatkowiak, A | 1 |
| Asten, P | 1 |
| Barrett, J | 1 |
| Weinstein, T | 2 |
| Korzets, A | 2 |
| Chagnac, A | 2 |
| Ori, Y | 2 |
| Herman, M | 2 |
| Zevin, D | 2 |
| Malachi, T | 2 |
| Gafter, U | 2 |
| Evans, WE | 1 |
| Hon, YY | 1 |
| Bomgaars, L | 1 |
| Coutre, S | 1 |
| Holdsworth, M | 1 |
| Janco, R | 1 |
| Kalwinsky, D | 1 |
| Keller, F | 1 |
| Khatib, Z | 1 |
| Margolin, J | 1 |
| Murray, J | 1 |
| Quinn, J | 1 |
| Ravindranath, Y | 1 |
| Ritchey, K | 1 |
| Roberts, W | 1 |
| Rogers, ZR | 1 |
| Schiff, D | 1 |
| Steuber, C | 1 |
| Tucci, F | 1 |
| Kornegay, N | 1 |
| Krynetski, EY | 1 |
| Relling, MV | 1 |
| McGeown, MG | 1 |
| Douglas, JF | 1 |
| Middleton, D | 1 |
| Stratta, P | 1 |
| Canavese, C | 1 |
| Santi, S | 1 |
| Ciccone, G | 1 |
| Rosso, S | 1 |
| Bumgardner, GL | 1 |
| Hardie, I | 1 |
| Johnson, RW | 1 |
| Lin, A | 1 |
| Nashan, B | 1 |
| Pescovitz, MD | 1 |
| Ramos, E | 1 |
| Vincenti, F | 1 |
| Nielsen, OH | 1 |
| Vainer, B | 1 |
| Rask-Madsen, J | 1 |
| Matuchansky, C | 1 |
| Schein, PS | 1 |
| Winokur, SH | 1 |
| Steinke, H | 1 |
| Laufs, R | 1 |
| Perings, E | 1 |
| Junge, U | 1 |
| Symington, GR | 1 |
| Mackay, IR | 1 |
| Lambert, RP | 1 |
| Mazzei, D | 1 |
| Polli, EE | 1 |
| Sieber, SM | 1 |
| Santiago Delpin, EA | 1 |
| Kinlen, LJ | 2 |
| Peto, J | 1 |
| Doll, R | 2 |
| Cameron, JS | 1 |
| Viteri, A | 1 |
| Vernace, SJ | 1 |
| Schaffner, F | 1 |
| Barbanel, C | 1 |
| Kreis, H | 1 |
| Crosnier, J | 1 |
| Czaja, AJ | 2 |
| Summerskill, WH | 1 |
| Verhaegen, H | 1 |
| De Cock, W | 1 |
| De Cree, J | 1 |
| Mitrou, PS | 1 |
| Fischer, M | 1 |
| Mitrou, G | 1 |
| Bach, JF | 1 |
| Dardenne, M | 1 |
| Pleau, JM | 1 |
| Bach, MA | 1 |
| Holm, O | 1 |
| O'Loughlin, JM | 1 |
| Bordes-Aznar, J | 1 |
| Mancilla, E | 1 |
| Rosenblum, M | 1 |
| Gabilondo, F | 1 |
| Orozco, R | 1 |
| Angeles, A | 1 |
| Alberú, J | 1 |
| Vilardell, J | 2 |
| Oppenheimer, F | 2 |
| Talbot-Wright, R | 1 |
| Ricart, MJ | 1 |
| Andreu, J | 1 |
| Alcaraz, A | 1 |
| Carretero, P | 1 |
| Tokoro, Y | 1 |
| Asano, T | 1 |
| Nakagouri, T | 1 |
| Ochiai, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, T | 1 |
| Sakamoto, K | 1 |
| Isono, K | 1 |
| Castelao, AM | 1 |
| Puig, JM | 1 |
| Cantarell, MC | 1 |
| Solá, R | 1 |
| Lauzurica, R | 1 |
| Dillon, TA | 1 |
| Sullivan, M | 1 |
| Schätzlein, MH | 1 |
| Peterson, AC | 1 |
| Scheeringa, RH | 1 |
| Clark, WR | 1 |
| Ladowski, JS | 1 |
| Matteson, EL | 1 |
| Hickey, AR | 1 |
| Maguire, L | 1 |
| Tilson, HH | 3 |
| Urowitz, MB | 1 |
| Excell, L | 1 |
| Peters, KM | 1 |
| Pfeiffer, R | 1 |
| Bornhofen, B | 1 |
| Ko, HL | 1 |
| Beuth, J | 1 |
| Grundmann, R | 1 |
| Pulverer, G | 1 |
| Russell, AS | 1 |
| Johnson, AG | 1 |
| Regal, J | 1 |
| Wang, KK | 1 |
| Beaver, SJ | 1 |
| Go, VL | 1 |
| Clements, PJ | 1 |
| Davis, J | 1 |
| Silman, AJ | 1 |
| Hazleman, B | 2 |
| Evans, SJ | 1 |
| Flavel, S | 1 |
| Hall, BM | 1 |
| Prati, GF | 1 |
| Recchia, G | 1 |
| Dean, P | 1 |
| Boschiero, L | 1 |
| Faccincani, L | 1 |
| Muolo, A | 1 |
| Chapman, JR | 1 |
| Morris, PJ | 1 |
| Tage-Jensen, U | 1 |
| Schlichting, P | 1 |
| Thomsen, HF | 1 |
| Høybye, G | 1 |
| Thomsen, AC | 1 |
| Whisnant, J | 1 |
| Krueger, TC | 1 |
| Tallent, MB | 1 |
| Richie, RE | 1 |
| Johnson, HK | 1 |
| MacDonell, RC | 1 |
| Turner, B | 1 |
| Lovisetto, P | 1 |
| Manachino, D | 1 |
| Biarese, V | 1 |
| Marchi, L | 1 |
| Andrione, P | 1 |
| Nashel, DJ | 1 |
| Van Scoik, KG | 1 |
| Johnson, CA | 1 |
| Porter, WR | 1 |
| Flatmark, A | 1 |
| Hartwich, G | 1 |
| McEwan, A | 1 |
| Petty, LG | 1 |
| Greenwald, ES | 1 |
| Groth, CG | 1 |
| Brettschneider, L | 1 |
| Smith, GV | 1 |
| Kashiwagi, N | 1 |
| Pauly, JL | 1 |
| Han, T | 1 |
| Varkarakis, MJ | 1 |
| Sokal, JE | 1 |
| Sampson, D | 1 |
| Murphy, GP | 1 |
| Allison, AC | 1 |
| Birkeland, SA | 1 |
| Kemp, E | 1 |
| Skinner, MD | 1 |
| Schwartz, RS | 1 |
| Videbaek, A | 1 |
| Diethelm, AG | 1 |
| Aldrete, JS | 1 |
| Shaw, JF | 1 |
| Cobbs, CG | 1 |
| Hartley, MW | 1 |
| Sterling, WA | 1 |
| Morgan, JM | 1 |
| Cerilli, J | 1 |
| Hattan, D | 1 |
| Evans, DB | 1 |
| Calne, RY | 1 |
| Guisan, Y | 1 |
| Enderlin, F | 1 |
| Harder, F | 1 |
| Brunner, F | 1 |
| Thiel, G | 1 |
| Bernhardt, JP | 1 |
| Schädeli, J | 1 |
| Mihatsch, M | 1 |
| Chlud, K | 1 |
| Ginn, HE | 1 |
| Woodruff, M | 1 |
| Kinlen, L | 1 |
| Reis, HE | 1 |
| Wilmanns, W | 1 |
| Leb, DE | 1 |
| Howell, RS | 1 |
| Hitchings, GH | 1 |
| Kölle, G | 1 |
| Kostanecki, W | 1 |
| Mazurkiewicz, W | 1 |
| Górkiewicz, A | 1 |
| Zborzil, J | 1 |
| Corder, MP | 1 |
| Young, RC | 1 |
| DeVita, VT | 1 |
| Ogston, D | 1 |
| Dawson, AA | 1 |
| Philip, JF | 1 |
| Kanis, SL | 1 |
| Modderman, S | 1 |
| Escher, JC | 1 |
| Erler, N | 1 |
| Beukers, R | 1 |
| de Boer, N | 1 |
| Bodelier, A | 1 |
| Depla, ACTM | 1 |
| Dijkstra, G | 1 |
| van Dijk, ARM | 1 |
| Gilissen, L | 1 |
| Hoentjen, F | 1 |
| Jansen, JM | 1 |
| Kuyvenhoven, J | 1 |
| Mahmmod, N | 1 |
| Mallant-Hent, RC | 1 |
| van der Meulen-de Jong, AE | 1 |
| Noruzi, A | 1 |
| Oldenburg, B | 1 |
| Oostenbrug, LE | 1 |
| Ter Borg, PCJ | 1 |
| Pierik, M | 1 |
| Romberg-Camps, M | 1 |
| Thijs, W | 1 |
| West, R | 1 |
| de Lima, A | 1 |
| van der Woude, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): a CanVasc Multicentre Study[NCT05716334] | 240 participants (Anticipated) | Observational | 2021-06-15 | Recruiting | |||
| MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis[NCT00748644] | Phase 3 | 117 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Tailoring Maintenance Therapy to CD5+ Regulatory B Cell Recovery in ANCA Vasculitis[NCT03906227] | 40 participants (Anticipated) | Interventional | 2019-06-28 | Recruiting | |||
| Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare[NCT02749292] | Phase 4 | 115 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200.) | ||
| Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis[NCT03920722] | Phase 3 | 8 participants (Actual) | Interventional | 2020-10-24 | Active, not recruiting | ||
| Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation[NCT02328885] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolescent, and Adult Lymphoblastic Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia[NCT02912676] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Depletion Induction With Rabbit Anti-Thymocyte Globulin, Followed by Two Approaches Toward Monotherapy Immunosuppression in Kidney Transplant Recipients[NCT00076570] | Phase 2 | 31 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation[NCT00166712] | Phase 4 | 40 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Study stopped due to lack of efficacy & funding.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of disease relapse added with the number of SAE in each group (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Number of events (Number) |
|---|---|
| B Cell Reconstitution | 27 |
| Serologic ANCA Flare | 36 |
The rituximab utilization was measured in how many times a subject received Rituximab throughout the study which was then averaged for all subjects in each treatment arm, including those who did not receive any infusion. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Infusions per subject (Mean) |
|---|---|
| B Cell Reconstitution | 3.6 |
| Serologic ANCA Flare | 0.5 |
The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) |
|---|---|
| B Cell Reconstitution | 4 |
| Serologic ANCA Flare | 7 |
Number of patients with serious adverse events (SAEs), including all episodes of late onset neutropenia (LON). SAE are defined in the Serious adverse event section. Serious adverse events were reported over the entire study period (5.5 years) (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 15 |
| Serologic ANCA Flare | 14 |
Hypogammaglobulinemia defined as an IgG < 250mg/dL (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 1 |
| Serologic ANCA Flare | 0 |
number of deaths throughout the study. (NCT02749292)
Timeframe: 5.5 years
| Intervention | number of deaths (Number) |
|---|---|
| B Cell Reconstitution | 2 |
| Serologic ANCA Flare | 0 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| Serologic ANCA Flare | 82 | 65 | 75 | 67 | 81 | 88 | 82 | 63 | 88 | 79 | 82 | 73 | 84 | 95 | 87 | 70 | 82 | 63 | 68 | 65 | 81 | 86 | 80 | 63 | 82 | 62 | 74 | 68 | 81 | 92 | 82 | 67 | 88 | 71 | 80 | 76 | 85 | 94 | 82 | 70 | 88 | 72 | 80 | 72 | 84 | 94 | 83 | 70 | 82 | 60 | 76 | 70 | 85 | 87 | 82 | 63 | 95 | 100 | 100 | 75 | 85 | 100 | 80 | 75 | 92 | 100 | 89 | 71 | 83 | 92 | 83 | 70 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 54 months | Role functioning/physical at 54 months | Role functioning/emotional at 54 months | Energy/fatigue at 54 months | Emotional well-being at 54 months | Social functioning at 54 months | Pain at 54 months | General health at 54 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| B Cell Reconstitution | 84 | 66 | 79 | 65 | 83 | 89 | 79 | 66 | 74 | 50 | 65 | 58 | 76 | 83 | 69 | 60 | 79 | 61 | 82 | 65 | 86 | 92 | 81 | 66 | 83 | 70 | 88 | 69 | 85 | 96 | 84 | 68 | 83 | 71 | 84 | 68 | 82 | 91 | 81 | 69 | 85 | 74 | 87 | 64 | 81 | 90 | 86 | 60 | 76 | 58 | 67 | 60 | 77 | 85 | 83 | 59 | 65 | 67 | 67 | 52 | 73 | 65 | 70 | 61 | 88 | 50 | 67 | 67 | 84 | 84 | 81 | 59 | 72 | 33 | 100 | 48 | 82 | 63 | 53 | 58 |
Number of infections mild and severe, whether they were treated or not with antibiotics (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) | |
|---|---|---|
| Serious Adverse Events- Infections | Adverse Events- Infections | |
| B Cell Reconstitution | 12 | 72 |
| Serologic ANCA Flare | 6 | 59 |
Relapses recording period was from 6/1/2016 to 12/31/2021. The outcome was reported as the number of participants with disease relapse who had either positive ANCA titers specific for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| PR3 | MPO | |
| B Cell Reconstitution | 1 | 4 |
| Serologic ANCA Flare | 7 | 7 |
The Vasculitis Damage Index (VDI) is a validated formal assessment tool in ANCA-associated vasculitis clinical trials. The VDI distinguishes vasculitis-induced chronic damage from active inflammation or persistent disease. Each item represents a disease manifestation and is given a score (of 1) if present for at least 3 months. Neither the cause of damage (vasculitis vs treatment) nor an ongoing activity are taken into consideration. The VDI includes 64 items categorized into 11 groups (by organ system) and the scored items are summed to give a total score ranging from 0 to 64. A higher score means more accrued damage. (NCT02749292)
Timeframe: 3 years starting at inclusion
| Intervention | score on a scale (Mean) | |
|---|---|---|
| VDI at inclusion | VDI at 3 years | |
| B Cell Reconstitution | 1.27 | 1.42 |
| Serologic ANCA Flare | 1.07 | 1.08 |
(NCT00076570)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| Sirolimus Group | 0 |
| Tacrolimus Group | 0 |
(NCT00076570)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| Sirolimus Group | 0 |
| Tacrolimus Group | 0 |
The incidence of rejection is determined by the proportion of patients experiencing biopsy proven acute allograft rejection during the first 12 months post-transplant. (NCT00166712)
Timeframe: Within 12 months post kidney transplant
| Intervention | Participants (Number) |
|---|---|
| Groups | 4 |
| Group 2 | 6 |
46 reviews available for azathioprine and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.
Topics: Adult; Azathioprine; Bone Marrow Diseases; Cyclophosphamide; Glucocorticoids; Herpes Zoster; Humans; | 2023 |
Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Myasthenia Gravis; Neoplasms; Prospective Studies | 2021 |
Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis.
Topics: Azathioprine; Graft Rejection; Humans; Immunosuppressive Agents; Mycophenolic Acid; Neoplasms; Organ | 2022 |
Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antirheumatic Agents; Azathioprine; Cycl | 2018 |
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
Topics: Azathioprine; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Immunosuppressive Agents; | 2018 |
Management of the ACC/AHA Stage D patient: cardiac transplantation.
Topics: Allografts; Azathioprine; Cardiotonic Agents; Contraindications; Graft Occlusion, Vascular; Graft Re | 2014 |
[Role of thiopurine agents in ulcerative colitis].
Topics: Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Disease Susceptibility; | 2011 |
Toxicity and response to thiopurines in patients with inflammatory bowel disease.
Topics: Azathioprine; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Crohn Disease; Humans; Im | 2015 |
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Animals; Azathioprine; Cladribine; Cl | 2010 |
Association between cancer and immunosuppressive therapy--analysis of selected studies in pemphigus and pemphigoid.
Topics: Azathioprine; Cyclophosphamide; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms; Pemphigoi | 2010 |
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathioprine; Cyclophospham | 2011 |
Presentation of idiopathic retroperitoneal fibrosis in the pediatric population.
Topics: Autoimmune Diseases; Azathioprine; Blood Sedimentation; Child; Combined Modality Therapy; Creatinine | 2003 |
Guidelines for prescribing azathioprine in dermatology.
Topics: Azathioprine; Contraindications; Drug Administration Schedule; Drug Monitoring; Evidence-Based Medic | 2004 |
Malignancy after transplantation.
Topics: Azathioprine; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Cyclosporine; Hepatitis, Viral, Hum | 2005 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclo | 2005 |
Post-transplant de novo malignancies in renal transplant recipients: the past and present.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Europe; Female; History, 20th Century; History, 21 | 2006 |
Azathioprine for multiple sclerosis.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Randomized Controlled | 2007 |
[Malignant tumors following renal transplantation].
Topics: Adrenal Cortex Hormones; Azathioprine; Calcineurin Inhibitors; Cyclosporine; Humans; Immunosuppressi | 2007 |
Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer.
Topics: Antineoplastic Agents; Azathioprine; Carcinogens; Cell Survival; Humans; Mercaptopurine; Neoplasms; | 2008 |
Azathioprine prescribing in neurology.
Topics: Autoimmune Diseases of the Nervous System; Azathioprine; Dose-Response Relationship, Drug; Drug Inte | 2008 |
The effect of chemotherapeutic agents on wound healing.
Topics: Adrenal Cortex Hormones; Anemia; Animals; Antineoplastic Agents; Azathioprine; Collagen; Cyclophosph | 1981 |
The price of immunotherapy.
Topics: Antilymphocyte Serum; Autoimmune Diseases; Azathioprine; B-Lymphocytes; Cyclophosphamide; Cyclospori | 1981 |
International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosp
Topics: Animals; Azathioprine; Chromosome Aberrations; Cyclosporine; Fetus; Humans; Neoplasms; Prednisone; R | 1994 |
Immunosuppressive agents in dermatology.
Topics: Azathioprine; Clinical Protocols; Cyclophosphamide; Cyclosporine; Humans; Immunosuppressive Agents; | 1993 |
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.
Topics: Azathioprine; Clinical Trials as Topic; DNA Damage; Female; Humans; Immunosuppressive Agents; Inflam | 2001 |
Immunosuppressive and cytotoxic chemotherapy: long-term complications.
Topics: Alkylating Agents; Antineoplastic Agents; Azathioprine; Bleomycin; Busulfan; Carcinogens; Chemical a | 1975 |
The action of antitumor agents: a double-edged sword?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azathioprine; Burkitt Lymphoma; Choriocarcinoma; | 1977 |
Principles of clinical immunosuppression.
Topics: Antilymphocyte Serum; Azathioprine; Cyclophosphamide; Graft Rejection; Humans; Immunologic Deficienc | 1979 |
Problems with immunosuppressive agents in renal disease.
Topics: Animals; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Immunosuppressive | 1975 |
Immunosuppressive drugs in renal transplantation. A review of the regimens.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Graft Rejection; Graft Survival; Humans; Immunocom | 1992 |
Immunosuppressive drugs in renal transplantation. A review of the regimens.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Graft Rejection; Graft Survival; Humans; Immunocom | 1992 |
Immunosuppressive drugs in renal transplantation. A review of the regimens.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Graft Rejection; Graft Survival; Humans; Immunocom | 1992 |
Immunosuppressive drugs in renal transplantation. A review of the regimens.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Graft Rejection; Graft Survival; Humans; Immunocom | 1992 |
Cytotoxic drugs: their clinical application to the rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Cell Division; Chemica | 1986 |
[Blood hypereosinophilias. IV. Symptomatic hypereosinophilias: connective tissue diseases, neoplasms, blood diseases, various causes].
Topics: Aged; Asthma; Azathioprine; Connective Tissue Diseases; Cortisone; Eosinophilia; Female; Hematologic | 1985 |
Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders.
Topics: Arthritis, Reactive; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophos | 1985 |
The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine.
Topics: Animals; Azathioprine; Biotransformation; DNA; DNA Replication; Humans; Immune System Diseases; Merc | 1985 |
[Immunosuppressive therapy in kidney transplantation].
Topics: Antilymphocyte Serum; Azathioprine; Dactinomycin; Humans; Immunosuppression Therapy; Kidney Transpla | 1971 |
[Cancerogenicity of cytostatics].
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azathioprine; Cell Transformation, Neoplastic; Da | 1971 |
Cancer chemotherapy. II.
Topics: Animals; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Cytarabine; Dactinomycin; Dau | 1972 |
Immunosuppressive therapy. 2.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Chlorambucil; Clin | 1972 |
[Immunosuppressive therapy. A survey concerning rationale, risks, indications and contraindications].
Topics: Adolescent; Adult; Azathioprine; Drug Therapy, Combination; Female; Humans; Immune System Diseases; | 1973 |
Immunology in neoplasia relating to diagnosis, therapy and transplantation. Immunosuppression and oncogenesis.
Topics: Adenocarcinoma; Animals; Antilymphocyte Serum; Azathioprine; Carcinogens; Cortisone; Humans; Immunos | 1974 |
Late medical complications of renal transplantation.
Topics: Adrenal Cortex Hormones; Adult; Allopurinol; Autoimmune Diseases; Azathioprine; Bone Diseases; Diabe | 1969 |
Immunosuppression and its complications.
Topics: Adrenal Cortex Hormones; Adult; Animals; Antibody Formation; Antigens; Antilymphocyte Serum; Autoimm | 1969 |
The role of immunosuppression in the genesis and growth of malignant tumours.
Topics: Animals; Antilymphocyte Serum; Azathioprine; Carcinogens; Humans; Immunologic Deficiency Syndromes; | 1971 |
[Antimetabolites].
Topics: Allopurinol; Animals; Antimetabolites; Azathioprine; Cell Division; Chemical Phenomena; Chemistry; C | 1971 |
Chemotherapy and comparative biochemistry: G. H. A. Clowes memorial lecture.
Topics: Allopurinol; Animals; Antimetabolites; Azathioprine; Binding Sites; Drug Therapy; Enzyme Inhibitors; | 1969 |
18 trials available for azathioprine and Neoplasms
| Article | Year |
|---|---|
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2014 |
20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Topics: Antilymphocyte Serum; Azathioprine; Combined Modality Therapy; Cyclosporine; Cytomegalovirus Infecti | 2008 |
Cyclosporine withdrawal improves long-term graft survival in renal transplantation.
Topics: Azathioprine; Cause of Death; Cyclosporine; Drug Administration Schedule; Female; Glomerular Filtrat | 2009 |
Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.
Topics: Adult; Azathioprine; Biopsy; Cardiovascular Diseases; Cause of Death; Chronic Disease; Cyclosporine; | 2003 |
Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
Topics: Adult; Azathioprine; Cardiovascular Diseases; Cause of Death; Cyclosporine; Follow-Up Studies; Human | 2007 |
Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2008 |
Triple therapy and incidence of de novo cancer in renal transplant recipients.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Cyclosporine; Drug Therapy, Combination; Female; Follo | 1994 |
Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.
Topics: Adenoma, Bile Duct; Age Factors; Azathioprine; Cyclosporine; Follow-Up Studies; Humans; Immunosuppre | 1993 |
A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
Topics: Adolescent; Adult; Aged; Antibody Formation; Azathioprine; Child; Cyclosporine; Drug Administration | 1993 |
Mycophenolate mofetil for maintenance therapy in kidney transplantation.
Topics: Antilymphocyte Serum; Azathioprine; Cytomegalovirus Infections; Diarrhea; Double-Blind Method; Graft | 1996 |
Randomized study with cyclosporine in kidney transplantation: 10-year follow-up.
Topics: Adolescent; Adult; Azathioprine; Cataract; Child; Creatinine; Cyclosporine; Female; Follow-Up Studie | 1996 |
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.
Topics: Adolescent; Adult; Aged; Area Under Curve; Azathioprine; Cyclosporine; Drug Administration Schedule; | 1998 |
Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation.
Topics: Adolescent; Adult; Aged; Azathioprine; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; G | 1998 |
Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
Topics: Acute Disease; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2001 |
Malignant neoplasms in renal transplant patients: a 24-year experience.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppression Therapy; Ki | 1992 |
Malignancies following long-term azathioprine treatment in chronic liver disease. A report from the Copenhagen Study Group for Liver Diseases.
Topics: Azathioprine; Hepatitis, Chronic; Humans; Liver Cirrhosis; Neoplasms | 1987 |
Pharmaco-epidemiology--drugs, arthritis, and neoplasms: industry contribution to the data.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Computers; Drug Industry; Humans; Leu | 1985 |
Immunosuppressive therapy. 2.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Chlorambucil; Clin | 1972 |
133 other studies available for azathioprine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
Topics: Animals; Drug Evaluation, Preclinical; Female; Neoplasms; Nitro Compounds; Quantitative Structure-Ac | 2008 |
Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Mycophenolic Acid; Neop | 2022 |
Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020.
Topics: Azathioprine; Brazil; Colitis, Ulcerative; Female; Humans; Male; Middle Aged; Neoplasms; Retrospecti | 2023 |
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials.
Topics: Adenosine Triphosphate; Adult; Azathioprine; Cancer Survivors; Clinical Trials as Topic; Electronic | 2023 |
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.
Topics: Adalimumab; Alkylating Agents; Antimetabolites; Azathioprine; Calcineurin Inhibitors; Cohort Studies | 2023 |
Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cause of Death; Cohort Studies; | 2021 |
Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study.
Topics: Adult; Aged; Azathioprine; Humans; Middle Aged; Multiple Sclerosis; Neoplasms; Retrospective Studies | 2021 |
Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease-Authors' reply.
Topics: Azathioprine; Humans; Inflammatory Bowel Diseases; Neoplasms | 2018 |
Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.
Topics: Aged; Aged, 80 and over; Azathioprine; Case-Control Studies; Denmark; Female; Humans; Male; Middle A | 2013 |
Use of azathioprine and the risk of cancer in inflammatory bowel disease.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azathioprine; Denmark; Female; Humans; Inflammatory Bo | 2013 |
High graft protection and low incidences of infections, malignancies and other adverse effects with intra-operative high dose ATG-induction: a single centre cohort study of 760 cases.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cohort Studies; Cyclosporine; Cytomegalovirus Infections; | 2013 |
Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Chi-Square Distr | 2013 |
Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Coh | 2014 |
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Topics: Adult; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Heart Transplantation; Humans; Immunos | 2015 |
[Applied pharmacogenetic].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azathioprine; Cyclosporine; Everolimus; Ge | 2016 |
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroi | 2016 |
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Azathioprine; Daclizumab | 2008 |
Immunosuppressive therapy and post-transplant malignancy.
Topics: Azathioprine; Calcineurin Inhibitors; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; My | 2009 |
Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.
Topics: Adult; Aged; Antimetabolites; Azathioprine; Case-Control Studies; Chi-Square Distribution; Female; H | 2010 |
Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Child, Preschool; Crohn Disease; Di | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Antibodies, Monoclonal; Azathioprine; Cost-Benefit Analysis; Crohn Disease; Drug Therapy, Combinatio | 2010 |
Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.
Topics: Adult; Azathioprine; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; | 2010 |
Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Topics: Adolescent; Adult; Azathioprine; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Ev | 2010 |
Azathioprine.
Topics: Animals; Antimetabolites, Antineoplastic; Azathioprine; Carcinogens; Humans; Neoplasms | 2011 |
Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.
Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Dermatomyositis; Diabetes Complications; Female; Fo | 2011 |
British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Azathioprine; Bone Marrow Diseases; Chemical and Drug Indu | 2011 |
Immunosuppression in patients with Crohn's disease and neoplasia: an ongoing clinical dilemma.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Mercaptopu | 2012 |
Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.
Topics: Adolescent; Adult; Age Distribution; Aged; Azathioprine; Colorectal Neoplasms; Drug Administration S | 2002 |
Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study.
Topics: Adult; Azathioprine; Comorbidity; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up St | 2003 |
De novo tumors after kidney transplantation: the Budapest experience.
Topics: Azathioprine; Cyclosporine; Female; Humans; Hungary; Immunosuppressive Agents; Kidney Transplantatio | 2003 |
SPLENIC HOMOTRANSPLANTATION.
Topics: Agammaglobulinemia; Azathioprine; Child; Dogs; Hypersplenism; Immunosuppressive Agents; Kidney Trans | 1964 |
SUCCESSFUL ALLOGENIC BONE MARROW TRANSPLANTATION IN MAN: CHIMERISM, INDUCED SPECIFIC TOLERANCE AND POSSIBLE ANTI-LEUKEMIC EFFECTS.
Topics: Antineoplastic Agents; Azathioprine; Bone Marrow Transplantation; Chimerism; Electrons; Genetic Dise | 1965 |
CADAVERIC RENAL HOMOTRANSPLANTATION WITH INADVERTENT TRANSPLANTATION OF CARCINOMA.
Topics: Antineoplastic Agents; Azathioprine; Carcinoma, Bronchogenic; Drug Therapy; Humans; Immunosuppressiv | 1965 |
The risk of cancer from azathioprine as a treatment for multiple sclerosis.
Topics: Azathioprine; Clinical Trials as Topic; Humans; Multiple Sclerosis; Neoplasms | 2004 |
Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus?
Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Male; Neoplasms; Time Factors; T | 2004 |
Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2004 |
Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Black People; Cause of Death; Diabetes Com | 2005 |
Extrathymic malignancies in patients with myasthenia gravis.
Topics: Adult; Age Factors; Age of Onset; Aged; Autoimmune Diseases; Azathioprine; Disease Progression; Fema | 2005 |
[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs].
Topics: Azathioprine; Cyclosporine; DNA Repair; Glucocorticoids; Humans; Immunosuppressive Agents; Mycopheno | 2005 |
Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients.
Topics: Azathioprine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Longitudinal Stud | 2006 |
Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.
Topics: Adult; Azathioprine; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Inc | 2006 |
[The occurrence of malignancies in a Hungarian lupus population].
Topics: Adult; Aged; Azathioprine; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Female; Gastroin | 2006 |
Risk factors for malignancy in Japanese renal transplant recipients.
Topics: Adult; Age Factors; Azathioprine; Cyclosporine; Female; Humans; Immunosuppressive Agents; Japan; Kid | 2007 |
Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Topics: Azathioprine; Cyclosporine; Enzyme Inhibitors; Heart Transplantation; Humans; Immunosuppressive Agen | 2007 |
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study.
Topics: Adult; Azathioprine; Case-Control Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Femal | 2008 |
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Topics: Adult; Azathioprine; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Digestive | 2008 |
Multiple sclerosis, hyperbaric oxygen and cancer.
Topics: Azathioprine; Humans; Hyperbaric Oxygenation; Multiple Sclerosis; Neoplasms | 1984 |
[Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience].
Topics: Adult; Azathioprine; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Multiple | 1984 |
[Chlorbutin, azathioprine, D-penicillamine, and levamisole (Decaris) in the treatment of rheumatoid arthritis patients. I. Comparative analysis of side effects].
Topics: Arthritis, Rheumatoid; Azathioprine; Bronchial Spasm; Chlorambucil; Drug Eruptions; Dyspepsia; Human | 1981 |
Azathioprine.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Female; Gastrointestinal Diseases; Humans; Leukopeni | 1984 |
Systemic lupus erythematosus and lymphoma. A family study.
Topics: Adult; Autoimmune Diseases; Azathioprine; Child; Drug Therapy, Combination; Female; Humans; Killer C | 1983 |
[The use of immunosuppressive drugs in the treatment of rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Cyclophosphamide; Humans; Immunosuppressive Agent | 1983 |
Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis.
Topics: Arteritis; Arthritis, Rheumatoid; Azathioprine; Chemical Phenomena; Chemistry; Cyclophosphamide; Hum | 1983 |
Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Bacterial Infections; Bone Marrow; Cardiovascular Disease | 1982 |
[Leukemia and other neoplasms possibly induced by immunosuppressors in non-malignant diseases (author's transl)].
Topics: Animals; Azathioprine; Chlorambucil; Cyclophosphamide; Humans; Immunosuppressive Agents; Leukemia; N | 1980 |
The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens.
Topics: Adult; Aged; Animals; Arthritis, Rheumatoid; Azathioprine; Carcinoma, Transitional Cell; Chromosome | 1982 |
An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today.
Topics: Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyclophosphamide; Female; Gold; Humans; Hydroxychl | 1982 |
Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities.
Topics: Adult; Aged; Anorexia; Arthritis, Rheumatoid; Azathioprine; Bacterial Infections; Chemical and Drug | 1982 |
Primary biliary cirrhosis: an increased incidence of extrahepatic malignancies?
Topics: Aged; Azathioprine; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Neoplasms; Retrospe | 1982 |
Occurrence of second tumors in man after anticancer drug treatment.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Azathiopri | 1982 |
Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Cyclophosphamide; Humans; Middle Age | 1980 |
Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy.
Topics: Actuarial Analysis; Adult; Azathioprine; Cardiomyopathies; Cyclosporine; Daunorubicin; Doxorubicin; | 1995 |
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Fe | 1994 |
Malignancy under immunosuppressive therapy including cyclosporine.
Topics: Adult; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Humans; Immunosuppress | 1994 |
Safety of low-dose purine analogues in inflammatory bowel disease.
Topics: Aged; Aged, 80 and over; Azathioprine; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Neoplasm | 1994 |
De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation.
Topics: Australia; Azathioprine; Cadaver; Cyclosporine; Female; Humans; Kidney Transplantation; Morbidity; N | 1993 |
Long-term safety of azathioprine therapy in multiple sclerosis.
Topics: Adenocarcinoma; Adult; Aged; Azathioprine; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Inci | 1993 |
Cancers in cyclosporine-treated vs azathioprine-treated patients.
Topics: Adult; Azathioprine; Child; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney Neoplasms | 1996 |
Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.
Topics: Adult; Age of Onset; Autoimmune Diseases; Azathioprine; Carcinogens; Case-Control Studies; Comorbidi | 1996 |
Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azathioprine; Cohort Studies; Female; Humans; | 1996 |
Tumors after renal transplantation.
Topics: Adult; Azathioprine; Child; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Huma | 1996 |
Study of malignancy among Egyptian kidney transplant recipients.
Topics: Azathioprine; Cyclosporine; Egypt; Female; Graft Survival; Humans; Immunosuppressive Agents; Inciden | 1997 |
Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; H | 1998 |
Characteristics of long-term renal transplant survivors.
Topics: Adolescent; Adult; Azathioprine; Cadaver; Child; Child, Preschool; Coronary Disease; Female; Follow- | 1998 |
Successful conversion from cyclosporine to azathioprine in elective renal transplant recipients.
Topics: Adult; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agen | 1998 |
Malignant neoplasm in kidney transplantation.
Topics: Adolescent; Adult; Azathioprine; CD4-Positive T-Lymphocytes; Cyclosporine; Female; Follow-Up Studies | 1998 |
The incidence of malignancy in heart transplant recipients.
Topics: Adult; Aged; Azathioprine; Cyclosporine; Female; Heart Transplantation; Humans; Immunosuppressive Ag | 1998 |
Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.
Topics: Aged; Aged, 80 and over; Azathioprine; Europe; Female; Follow-Up Studies; Humans; Immunosuppressive | 1999 |
Effect of immunosuppressive therapy on DNA repair and cancer incidence in renal transplant recipients.
Topics: Adult; Aged; Azathioprine; Cyclosporine; DNA Repair; Drug Therapy, Combination; Female; Humans; Immu | 2000 |
Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cyclosporine; DNA Repair; Dose-Resp | 2001 |
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azathioprine; Child; Child, Preschool; Female; G | 2001 |
One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre.
Topics: Azathioprine; Cyclosporine; Female; Hospitals, Urban; Humans; Immunosuppressive Agents; Ireland; Kid | 2000 |
Systemic lupus erythematosus.
Topics: Antiphospholipid Syndrome; Azathioprine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunogl | 2001 |
Inflammatory bowel diseases 1977.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Cromolyn Sodium; Diet; Eye Diseases; Humans; Joint | 1977 |
The effect of an immunosuppressive drug (azathioprine) on the latent infection of marmoset monkeys (Callithrix jacchus) with the oncogenic Herpesvirus saimiri.
Topics: Animals; Azathioprine; Callitrichinae; Disease Models, Animal; Haplorhini; Herpesviridae; Herpesviri | 1975 |
Cancer and teratogenesis: infrequent occurrence after medical use of immunosuppressive drugs.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous C | 1977 |
Malignancy after immunosuppressive therapy.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Dermatomyositis; Female; Humans; Immunosuppression Therap | 1977 |
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs.
Topics: Adolescent; Adult; Aged; Australia; Azathioprine; Chlorambucil; Cyclophosphamide; Female; Follow-Up | 1979 |
Extrahepatic malignancy in chronic liver disease: report of six cases.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Chronic Disease; Cystadenocarcinoma; Female; Hepatitis | 1976 |
[Long-term use of immunosuppressants in patients with kidney transplants].
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Gastro | 1975 |
Malignancy in chronic liver disease.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Diseases; Middle Ag | 1977 |
The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients.
Topics: Azathioprine; Humans; Levamisole; Lymphocytes; Neoplasms; Rosette Formation | 1977 |
[Oncogenesis due to immunosuppressive agents (cytostatics) in (NZBxNZW) mice].
Topics: Animals; Azathioprine; Cyclophosphamide; Female; Mice; Mice, Inbred NZB; Mice, Inbred Strains; Neopl | 1976 |
Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human.
Topics: Aging; Animals; Antilymphocyte Serum; Arthritis, Rheumatoid; Autoantibodies; Azathioprine; Cell-Free | 1975 |
[Immunologic tissue damage and immunosuppression].
Topics: Abnormalities, Drug-Induced; Azathioprine; Cortisone; Cyclophosphamide; Female; Humans; Immunosuppre | 1976 |
Infections in the immunosuppressed patient.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Azathioprine; Bacteria; Bacterial | 1975 |
Increased risk of malignant tumors in renal transplant recipients receiving cyclosporine.
Topics: Adult; Azathioprine; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation | 1992 |
A statistical study of cancer incidence in renal transplant patients.
Topics: Adolescent; Adult; Azathioprine; Child; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kid | 1992 |
Cancer after transplantation in Catalonia.
Topics: Adult; Azathioprine; Cadaver; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transp | 1992 |
Cardiac transplantation in patients with preexisting malignancies.
Topics: Adult; Azathioprine; Cyclosporins; Female; Follow-Up Studies; Graft Rejection; Heart Transplantation | 1991 |
Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azathioprine; Female; Humans; Incidence; Lymp | 1991 |
Cancer development in cadaveric donor renal allograft recipients treated with azathioprine (AZA) or cyclosporine (CyA) or AZA/CyA.
Topics: Age Factors; Azathioprine; Cadaver; Cyclosporins; Drug Therapy, Combination; Humans; Immunosuppressi | 1991 |
Comparative study on lymphocyte subpopulations in cancer patients after immunostimulation with propionibacteria and in renal transplant patients after combined immunosuppression.
Topics: Azathioprine; Globulins; Humans; Immunization; Immunosuppressive Agents; In Vitro Techniques; Kidney | 1990 |
Comment on the article by Singh et al.
Topics: Azathioprine; Humans; Neoplasms | 1990 |
Immunotoxicity of immunotherapeutic agents.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Azathioprine; Cyclophosphamide; Cyclosporins; Glucocorticoids; Go | 1985 |
Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.
Topics: Azathioprine; Chronic Disease; Female; Hepatitis; Hepatitis B Surface Antigens; Humans; Immunosuppre | 1989 |
Pharmacoepidemiology: the industry's perspective.
Topics: Arthritis, Rheumatoid; Azathioprine; Decision Making; Drug Industry; Epidemiology; Humans; Immune Sy | 1988 |
Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.
Topics: Arthritis, Rheumatoid; Azathioprine; Follow-Up Studies; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; | 1988 |
Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine.
Topics: Australia; Azathioprine; Carcinoma, Squamous Cell; Cyclosporins; Female; Humans; Kidney Transplantat | 1987 |
[Malignant neoplastic pathology in patients given a kidney transplant].
Topics: Azathioprine; Humans; Immunosuppression Therapy; Kidney Transplantation; Lymphoma; Neoplasms; Sarcom | 1987 |
Long-term effects of short-term cyclosporine.
Topics: Adult; Azathioprine; Cyclosporins; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejec | 1986 |
Neoplasia in immunosuppressed renal transplant patients: a 20-year experience.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Azathioprine; Cadaver; Child; Child, Preschool; Cyclo | 1985 |
Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Cyclophosphamide; Cystitis; Humans; Immunosuppres | 1985 |
Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squa | 1985 |
Oncogenicity of immunosuppressive drugs.
Topics: Animals; Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Mice; Neoplasms; Neoplasm | 1972 |
Perspectives in organ transplantation.
Topics: Adult; Alpha-Globulins; Antigens; Antilymphocyte Serum; Azathioprine; Beta-Globulins; Cadaver; Elect | 1969 |
Leukocyte (3H) thymidine uptake in short-term whole-blood cultures of human and canine renal allograft recipients.
Topics: Animals; Azathioprine; Cadaver; Dogs; Graft Rejection; Hodgkin Disease; Humans; Immunity, Cellular; | 1973 |
Tumour development following immunosuppression.
Topics: Adult; Animals; Antilymphocyte Serum; Azathioprine; Child; Cricetinae; Female; Humans; Immunity, Cel | 1970 |
Malignant tumours following immunosuppression in renal transplantation.
Topics: Adenocarcinoma; Adult; Azathioprine; Brain Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinom | 1973 |
Clinical evaluation of equine antithymocyte globulin in recipients of renal allografts: Analysis of survival, renal function, rejection, histocompatibility, and complications.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Azathioprine; Bone Diseases; Child; Evaluation Stu | 1974 |
Renal transplantation in patients with carcinoma.
Topics: Adult; Angiography; Azathioprine; Cadaver; Female; Graft Rejection; Hematuria; Humans; Immunosuppres | 1974 |
[Malignant tumors following transplantation. Case reports and review of the literature].
Topics: Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Graft Rejection; Humans; Kidney | 1973 |
[Clinical picture of rheumatologic diseases. Current status of cytostatic therapy].
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Cyclophosphamide; Humans; | 1974 |
Immunosurveillance and cancer: epidemiological evidence.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Chediak-Higashi Syndrome; Child; Child, Preschoo | 1970 |
Immunosuppressive drugs. I.
Topics: Adrenal Cortex Hormones; Animals; Antibodies; Antibody Formation; Antilymphocyte Serum; Antineoplast | 1970 |
Carcinoma of the testis in a renal transplant recipient.
Topics: Adult; Azathioprine; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Kidney Trans | 1971 |
[Clinical aspects of immunosuppressive therapy in childhood rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Arthritis, Juvenile; Azathioprine; Child; Humans; Immuni | 1972 |
[Hair changes in immunosuppressive therapy].
Topics: Antineoplastic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Hair; Humans; Immunosuppression | 1971 |
Delayed hypersensitivity in patients with cancer.
Topics: Azathioprine; Croton Oil; Hodgkin Disease; Humans; Hypersensitivity, Delayed; Immunosuppressive Agen | 1971 |
Complications of immunosuppression.
Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Azathioprine; Bone Marrow Diseases; Humans; Immunosup | 1971 |
Methotrexate and the platelet count.
Topics: Antineoplastic Agents; Azathioprine; Blood Cell Count; Blood Platelets; Fluorouracil; Humans; Leukop | 1968 |
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Topics: Adalimumab; Adult; Anti-Bacterial Agents; Autoimmune Diseases; Cesarean Section; Child Development; | 2021 |